Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer

Journal of Urology

Volumn 170, Issue 3, 2003, Pages 964-969

  Böhle, Andreas ^a   Brandau, Sven ^b  

^a HELIOS AGNES KARLL HOSPITAL   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Bladder; Bladder neoplasms; Immunotherapy; Mycobacterium bovis

Indexed keywords

BCG VACCINE;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MEDICAL INFORMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUPERFICIAL CANCER; TARGET ORGAN;

EID: 0041736386     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000073852.24341.4a     Document Type: Review

References (66)

1. Morales, A., Eidinger, D. and Bruce, A. W.: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol, 116: 180, 1976
2. Ratliff, T. L., Hudson, M. A. and Catalona, W. J.: Strategy for improving therapy of superficial bladder cancer. World J Urol, 9: 95, 1991
3. Chapman, P. B. and Houghton, A. N.: Non-antibody immunotherapy of cancer. Curr Opin Immunol, 5: 726, 1993
4. Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B. et al: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med, 325: 1205, 1991
5. Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Crissman, J. D., Lowe, B. A., Smith, J. A., Jr. et al: Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. Urol Oncol, 1: 119, 1995
6. Malmström, P.-U., Wijkström, H., Lundholm, C., Wester, K., Busch, C., Norlén, B. J. et al: 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol, 161: 1124, 1999
7. Herr, H. W., Laudone, V. P., Badalament, R. A., Oettgen, H. F., Sogani, P. C., Freedman, B. D. et al: Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol, 6: 1450, 1988
8. Herr, H. W.: Surgical therapy of high-risk bladder carcinoma. Transurethral resection (TUR) alone vs adjuvant BCG. In: Optimal Therapy for Patients With High-Risk Superficial Bladder Cancer - Controversy and Consensus. Proceedings of the First Lübeck Symposium on Bladder Cancer, Lübeck, Germany, May 31, 1997. Lübeck, Germany: The Medicine Publishing Foundation, No. 37, pp. 45-49, 1997
9. Lamm, D. L., Blumenstein, B. A., Crissman, J. D., Montie, J. E., Gottesman, J. E., Lowe, B. A. et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol, 163: 1124, 2000
10. Sylvester, R. J., van der Meijden, A. P. M. and Lamm, D. L.: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol, 168: 1964, 2002
11. Mahairas, G. G., Sabo, P. J., Hickey, M. J., Singh, D. C. and Stover, C. K.: Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol, 178: 1274, 1996
12. Behr, M. A., Wilson, M. A., Gill, W. P., Salamon, H., Schoolnik, G. K., Rane, S. et al: Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science, 284: 1520, 1999
13. Schamhart, D. H., de Boer, E. C., de Reijke, T. M. and Kurth, K.: Urinary cytokines reflecting the immunological response in the urinary bladder to biological response modifiers: their practical use. Eur Urol, suppl., 37: 16, 2000
14. Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. and Smyth, J. F.: Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol, 147: 1636, 1992
15. Lage, J. M., Bauer, W. C., Kelley, D. R., Ratliff, T. L. and Catalona, W. J.: Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer. J Urol, 135: 916, 1986
16. de Boer, E. C., Somogyi, L., de Ruiter, G. J., de Reijke, T. M., Kurth, K. H. and Schamhart, D. H.: Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res, 25: 31, 1997
17. Thalmann, G. N., Dewald, B., Baggiolini, M. and Studer, U. E.: Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol, 158: 1340, 1997
18. Thalmann, G. N., Sermier, A., Rentsch, C., Möhrle, K., Cecchini, M. G. and Studer, U. E.: Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol, 164: 2129, 2000
19. Jackson, A. M., Ivshina, A. V., Senko, O., Kuznetsova, A., Sundan, A., O'Donnell, M. A. et al: Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndromes analysis. J Urol, 159: 1054, 1998
20. Jackson, A. M., Alexandroff, A. B., Kelly, R. W., Skibinska, A., Esuvaranathan, K., Prescott, S. et al: Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol, 99: 369, 1995
21. Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. and Smyth, J. F.: Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol, 144: 1248, 1990
22. Haaff, E. O., Catalona, W. J. and Ratliff, T. L.: Detection of interleukin-2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol, 136: 970, 1986
23. De Boer, E. C., De Jong, W. H., Steerenberg, P. A., Aarden, L. A., Tetteroo, E., De Groot, E. R. et al: Induction of urinary interleukin-1 (IL-1), IL-2, IL-6 and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol Immunother, 34: 306, 1992
24. Bohle, A., Nowc, C., Ulmer, A. J., Musehold, J., Gerdes, J., Hofstetter, A. G. et al: Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma Cytokine, 2: 175, 1990
25. H2 cytokine, following bacillus Calmette-Guérin immunotherapy of bladder cancer. Int J Oncol, 9: 179, 1996
26. Poppas, D. P., Pavlovich, C. P., Folkman, J., Voest, E. E., Chen, X., Luster, A. D. et al: Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10 Urology, 52: 268, 1998
27. Chen, X., Luo, Y., Yamada, H. and O'Donnell, M. A.: BCG potentiates human chemokine induction in vivo and in vitro. J Urol, suppl., 165: 114, abstract 465, 2001
28. Böhle, A., Gerdes, J., Ulmer, A. J., Hofstetter, A. G. and Flad, H.-D.: Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol, 144: 53, 1990
29. de Boer, E. C., de Jong, W. H., van der Meijden, A. P., Steerenberg, P. A., Witjes, F., Vegt, P. D. et al: Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res, 19: 45, 1991
30. Jackson, A. M., Alexandroff, A. B., McIntyre, M., Esuvaranathan, K., James, K. and Chisholm, G. D.: Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. J Clin Pathol, 47: 309, 1994
31. Fleischmann, J. D., Toossi, Z., Ellner, J. J., Wentworth, D. B., Ratliff, T. L. and Imbembo, A. L.: Urinary interleukins in patients receiving intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. Cancer, 64: 1447, 1989
32. de Reijke, T. M., de Boer, E. C., Kurth, K. H. and Schamhart, D. H. J.: Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol, 155: 477, 1996
33. Kaempfer, R., Gerez, L., Farbstein, H., Madar, L., Hirschman, O., Nussinovich, R. et al: Prediction of response to treatment in superficial bladder carcinoma through pattern of Interleukin-2 gene expression. J Clin Oncol, 14: 1778, 1996
34. Soloway, M. S.: Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res, 37: 2918, 1977
35. Gunther, J. H., Jurczok, A., Wulf, T., Brandau, S., Deinert, I., Jocham, D. et al: Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res, 59: 2834, 1999
36. Ratliff, T. L., Palmer, J. O., McGarr, J. A. and Brown, E. J.: Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res, 47: 1762, 1987
37. Zhao, W., Schorey, J. S., Bong-Mastek, M., Ritchey, J., Brown, E. J. and Ratliff, T. L.: Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer, 86: 83, 2000
38. Kavoussi, L. R., Brown, E. J., Ritchey, J. K. and Ratliff, T. L.: Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement of the expression of an antitumor response. J Clin Invest, 85: 62, 1990
39. Ratliff, T. L., Gillen, D. and Catalona, W. J.: Requirement of a thymus dependent immune response for BCG-mediated anti-tumor activity. J Urol, 137: 155, 1987
40. Ratliff, T. L., Ritchey, J. K., Yuan, J. J. J., Andriole, G. L. and Catalona, W. J.: T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol, 150: 1018, 1993
41. Brandau, S., Riemensberger, J., Jacobsen, M., Kemp, D., Zhao, W., Zhao, X. et al: NK cells are essential for effective BCG immunotherapy. Int J Cancer, 92: 697, 2001
42. McAveney, K. M., Gomella, L. G. and Lattime, E. C.: Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy. Cancer Immunol Immunother, 39: 401, 1994
43. Shin, J. S., Park, J. H., Kim, J. D., Lee, J. M. and Kim, S. J.: Induction of tumour necrosis factor-alpha (TNF-alpha) mRNA in bladders and spleens of mice after intravesical administration of bacillus Calmette-Guerin. Clin Exp Immunol, 100: 26, 1995
44. Brandau, S., Riemensberger, J. and Böhle, A.: Role of IFN-gamma and IL-10 in immunotherapy of bladder cancer with Mycobacterium bovis BCG. Immunobiology, 203: 350, 2000
45. Hawkyard, S. J., Jackson, A. M., James, K., Prescott, S., Smyth, J. F. and Chisholm, G. D.: The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol, 147: 1399, 1992
46. Thanhauser, A., Bohle, A., Flad, H. D., Ernst, M., Mattern, T. and Ulmer, A. J.: Induction of bacillus Calmette-Guerin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother, 37: 105, 1993
47. de Reijke, T. M., Vos, P. C., Bevers, R. F., de Muinck Keizer, W. H., Kurth, K. H. and Schamhart, D. H.: Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG). Urol Res, 21: 349, 1993
48. Esuvaranathan, K., Alexandroff, A. B., McIntyre, M., Jackson, A. M., Prescott, S., Chisholm, G. D. et al: Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol, 154: 572, 1995
49. Pryor, K., Stricker, P., Russell, P., Golovsky, D. and Penny, R.: Antiproliferative effects of bacillus Calmette-Guerin and Interferon alpha-2b on human bladder cancer cells in vitro. Cancer Immunol Immunother, 41: 309, 1995
50. Pryor, K., Goddard, J., Goldstein, D., Stricker, P., Russell, P., Golovsky, D. et al: Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer, 71: 801, 1995
51. Mizutani, Y., Nio, Y., Fukumoto, M. and Yoshida, O.: Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer, 69: 537, 1992
52. Thanhäuser, A., Böhle, A., Schneider, B., Reiling, N., Mattern, T., Ernst, M. et al: The induction of bacillus-Calmette-Guérin activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother, 40: 103, 1995
53. Brandau, S. and Bohle, A.: Activation of natural killer cells by Bacillus Calmette-Guerin. Eur Urol, 39: 518, 2001
54. Brandau, S., Suttmann, H., Riemensberger, J., Seitzer, U., Arnold, J., Durek, C. et al: Perforin-mediated lysis of tumor cells by Mycobacterium Bovis Bacillus Calmette-Guerin-activated killer cells. Clin Cancer Res, 6: 3729, 2000
55. Reiss, K., Brandau, S., Ulmer, A. J., Flad, H.-D., Jocham, D. and Böhle, A.: BCG-immunotherapy of superficial bladder cancer: BCG-induced activation of MNCs is regulated by cytokines. Eur Urol, 36: 476, 1999
56. O'Donnell, M. A., Luo, Y., Chen, X., Szilvasi, A., Hunter, S. E. and Clinton, S. K.: Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin. J Immunol, 163: 4246, 1999
57. Mendez-Samperio, P., Ayala-Verdin, H. E. and Trejo-Echeverria, A.: Interleukin-12 regulates the production of Bacille Calmette-Guerin-induced interferon-gamma from human cells in a CD40-dependent manner. Scand J Immunol, 50: 61, 1999
58. Luo, Y., Chen, X., Downs, T. M., DeWolf, W. C. and O'Donnell, M. A.: IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol, 162: 2399, 1999
59. Chin, J. L., Kadhim, S. A., Batislam, E., Karlik, S. J., Garcia, B. M., Nickel, J. C. et al: Mycobacterium cell wall: an alterna alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. J Urol, 156: 1189, 1996
60. Kelley, D. R., Ratliff, T. L., Catalona, W. J., Shapiro, A., Lage, J. M., Bauer, W. C. et al: Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J Urol, 134: 48, 1985
61. Shapiro, A., Ratliff, T. L., Oakley, D. M. and Catalona, W. J.: Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guerin and its correlation with bacillus Calmette-Guerin viability and natural killer cell activity. Cancer Res, 43: 1611, 1983
62. Glashan, R. W.: A randomized controlled study of intravesical α-2b-interferon in carcinoma in situ of the bladder. J Urol, 144: 658, 1990
63. Stricker, P., Pryor, K., Nicholson, T., Goldstein, D., Golovsky, D., Ferguson, R. et al: Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology, 48: 957, 1996
64. Clinton, S. K., Canto, E. and O'Donnell, M. A.: Interleukin-12. Opportunities for the treatment of bladder cancer. Urol Clin N Am, 27: 147, 2000
65. O'Donnell, M. A., Aldovini, A., Duda, R. B., Yang, H., Szilvasi, A., Young, R. A. et al: Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun, 62: 2508, 1994
66. Luo, Y., Chen, X., Han, R. and O'Donnell, M. A.: Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol, 123: 264, 2001